Phio Pharmaceuticals

Phio Pharmaceuticals stock rose about 57.8% in pre-market trading after the company published convincing efficacy results from the phase‑1b study of PH-762. In the final cohort 6 of 7 patients responded pathologically (85%), four of them with complete remissions. Among the 22 patients in the dose‑escalation cohorts there were no serious adverse events or dose‑limiting toxicities. Phio reported an overall response rate of 65% in squamous cell carcinomas (13 of 20 patients) and plans to submit an FDA request on further trial design in Q2 2026; CMC material for animal studies is expected to be available in March 2026. » Plus sur de.investing.com

Phio Pharmaceuticals will begin a toxicology study for the skin cancer drug PH-762 in Q1 2026 after the FDA approved the study design. The non‑clinical study is a prerequisite for registration‑relevant human trials; part of the recent financing is intended to support development and FDA‑compliant manufacturing standards in 2026. Parallelly, the company reports promising Phase‑1b data: of 16 cSCC patients, six achieved complete remissions with no dose‑limiting toxicities. Phio has more liquidity than debt but is burning cash quickly; analysts see a $14 price target despite the current stock pullback and micro‑cap market capitalization. » Plus sur de.investing.com

Phio Pharmaceuticals' INTASYL therapeutic PH-762 received the "Immunomodulatory Solution of the Year" award. PH-762 is being tested in a phase 1b study against various skin cancers and showed complete tumor remissions or significant reductions in three patients. The stock fell by about 28% last week, while the company raised roughly $13.4 million through the exercise of warrants. Investors are focused on the quarterly results scheduled for November 11 and the further progress of the clinical program. » Plus sur de.investing.com